AnaCardio

All Fund articles Fund PR Portfolio articles Portfolio PR

AnaCardio´s Phase 1b/2a GOAL-HF1 study in patients with Heart Failure and Reduced Ejection Fraction (HFrEF) published in The Lancet

2026.06.252026.06.29 / Favourable safety profile in marked contrast to traditional inotropic therapeutics AC01 showed rapid and sustained improvements in cardiac output, structure and function STOCKHOLM, Sweden, [D ...

Listen in to Professor Lars Lund, founder at AnaCardio, discussing the findings from GOAL-HF1, the first study using our oral ghrelin agonist, AC01, in patients with HFrEF

2026.06.082026.06.29 / https://soundbioventures.com/wp-content/uploads/2026/06/HFA-2026_-AC01-in-HFrEF-—-Safety-and-Efficacy-from-GOAL-HF1-_-AnaCardio-1.html ...

AnaCardio Announces Phase 1b/2a GOAL-HF1 Results of AC01 Demonstrating Favorable Safety and Sustained Improvements in Cardiac Function on Top of Standard-of-Care Therapy in HFrEF

2026.05.112026.05.18 / STOCKHOLM, Sweden, May 11, 2026 – AnaCardio today announced detailed results from its Phase 1b/2a GOAL-HF1 study evaluating AC01 in patients with heart failure with reduced ejection fraction (HFrEF), ...

AnaCardio’s AC01 Phase 1b/2a HFrEF Study Selected for Late-Breaking Science Presentation at the Heart Failure 2026 Congress

2026.03.262026.03.26 / STOCKHOLM, Sweden – March 26, 2026 – AnaCardio today announces that the results from GOAL-HF1, its Phase 1b/2a study of AC01 in patients with heart failure with reduced ejection fraction (HFrEF) have ...

AnaCardio announces issuance of U.S. patent for AC01, strengthening protection into the 2040s

2026.03.112026.03.11 / Stockholm, Sweden and Lugano, Switzerland, March 11, 2026 - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure and Helsinn ...

AnaCardio Announces Completion of Target Enrollment in Phase 2a Study of AC01 in Heart Failure; Results Expected Year-end 2025

2025.09.172025.12.02 / Stockholm, Sweden, September 16, 2025 – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents for heart failure, today announced that its ongoing Phase 2a study of ...

AnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial Officer

2025.09.022025.12.02 / Stockholm, Sweden, September 2, 2025 - AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces to ...

AnaCardio announces positive scientific advice from the FDA and EMA, establishing a favourable development path for AC01 treatment of chronic HFrEF

2025.07.172025.09.22 / Alignment reached with both the FDA and EMA on key elements of the AC01 development strategy in chronic HFrEF, allowing for a lean, straightforward and coherent plan across both Europe and the USA ...

AnaCardio receives patent grant in Europe for AC01

2025.03.132025.04.30 / Stockholm, Sweden and Lugano, Switzerland, March 13, 2025 - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure and Helsinn ...

AnaCardio reports first patient dosed in the phase 2a study evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF)

2025.02.272025.04.30 / February 25, 2025, Stockholm, Sweden - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure today announced that the first pa ...

Applying the best of both science and business to treat heart failure

2025.01.312025.04.30 / AnaCardio is focused on bringing treatment for one of today’s largest unmet medical needs to market. According to CEO Patrik Strömberg, the Swedish biopharmaceutical company is leveraging strong scie ...

AnaCardio press release

2025.01.092025.12.02 / AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure Reports positive results from phase 1b study of AC01 in patients with heart failure and reduce ...